CGEM
HealthcareCullinan Therapeutics, Inc. · Medical - Pharmaceuticals · $850M
What is Cullinan Therapeutics, Inc.?
Cullinan Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies in oncology and immuno-oncology. Headquartered in Cambridge, MA, the company is building a pipeline of novel cancer treatments across multiple tumor types.
Cullinan Therapeutics advances a portfolio of oncology drug candidates through clinical trials, generating no product revenue at this stage. The company's approach centers on identifying cancer targets where novel biologics or small molecules may offer meaningful patient benefit. Revenue generation depends on future regulatory approvals, partnerships, or licensing deals — a model common among clinical-stage biotechs that prioritizes pipeline progress over near-term profitability.
Cullinan Therapeutics was founded in 2016 and is headquartered in Cambridge, Massachusetts.
- CLN-978: a bispecific T-cell engager targeting B-cell malignancies
- Zipalertinib (CLN-081): an EGFR-mutant non-small cell lung cancer candidate
- CLN-619: an immuno-oncology program targeting solid tumors
- CLN-049: a bispecific antibody candidate in oncology
- CLN-617: an additional pipeline asset in immuno-oncology
Is CGEM a Good Stock to Buy?
UQS Score rates CGEM as Poor overall, reflecting the early-stage nature of the business across most evaluated dimensions.
The Risk pillar stands out as the relative bright spot in Cullinan's profile — a notable distinction for a clinical-stage biotech where balance sheet management and cash runway are critical. This suggests the company has maintained a degree of financial discipline that provides some buffer as it advances its pipeline.
Quality, Moat, Growth, and Valuation all register as weak or elevated, which is typical for pre-revenue biotechs but signals meaningful uncertainty. The Elevated Valuation label suggests the market may already be pricing in optimistic pipeline outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CGEM pay dividends?
No — Cullinan Therapeutics, Inc. does not currently pay a dividend.
Cullinan Therapeutics does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials and pipeline development. Investors in CGEM are typically seeking long-term value through potential drug approvals or partnership milestones rather than income.
When does CGEM report earnings?
Cullinan Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash position, operating expenses, and pipeline progress rather than traditional revenue or profit metrics. Key updates tend to center on clinical trial milestones and any partnership or licensing developments.
For the most recent quarter's results and pipeline updates, visit Cullinan Therapeutics' investor relations page directly.
CGEM Price History
-52.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Cullinan Therapeutics, Inc.?
Based on Cullinan Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CGEM Long-term Outlook
Cullinan's near-term trajectory is shaped almost entirely by clinical trial outcomes rather than commercial fundamentals. The Weak Growth pillar reflects the absence of revenue-generating products, while the Good Risk label suggests the company has managed its financial position with some care. The Elevated Valuation pillar indicates that current market pricing may leave limited margin of safety if pipeline milestones are delayed or disappointing. Progress in any of its lead programs — particularly Zipalertinib or CLN-978 — could meaningfully shift the fundamental outlook.
Growth drivers
- Positive clinical data readouts from lead pipeline candidates
- Potential partnership or licensing agreements with larger pharmaceutical companies
- Expansion into additional oncology indications leveraging existing platform biology
Key risks
- Clinical trial failure or safety signals in any lead program
- Elevated valuation leaving little room for setbacks
- Ongoing cash consumption with no near-term revenue visibility
CGEM vs Peers
Cullinan Therapeutics operates in a crowded clinical-stage biotech landscape alongside other development-stage companies pursuing niche therapeutic areas.
Atai focuses on mental health and neuropsychiatric conditions rather than oncology, representing a distinct therapeutic focus from Cullinan's cancer-centered pipeline.
Galecto pursues fibrosis and oncology targets through galectin inhibition, offering a different mechanistic approach compared to Cullinan's bispecific and EGFR-focused programs.
High Tide operates in cannabis retail rather than biopharma, making it a structurally different business despite sharing the small-cap development-stage profile.
Frequently Asked Questions
What does Cullinan Therapeutics do?
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies. Its pipeline targets oncology and immuno-oncology indications, with candidates including bispecific T-cell engagers and EGFR-mutant lung cancer treatments. The company has not yet commercialized any products and is focused on advancing its pipeline through clinical trials.
Does CGEM pay dividends?
No, Cullinan Therapeutics does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and development. Investors in CGEM are generally seeking returns through pipeline value creation rather than income distributions.
When does CGEM report earnings?
Cullinan Therapeutics reports on a quarterly basis, in line with standard US public company requirements. Because it is pre-revenue, reports focus on cash runway and clinical updates rather than traditional earnings metrics. Check the company's investor relations page for the most current schedule.
Is CGEM a good stock to buy?
UQS Score rates CGEM as Poor overall, driven by Weak readings across Quality, Moat, and Growth pillars. The Risk pillar is a relative positive. Whether CGEM suits a particular investor depends on their risk tolerance and view on the pipeline — the full UQS breakdown is available to Pro members.
Is CGEM overvalued?
The UQS Valuation pillar for CGEM is rated Elevated, suggesting the current market price may reflect optimistic assumptions about pipeline success. For a pre-revenue biotech, valuation is inherently speculative and tied closely to clinical trial outcomes rather than current financial performance.
How does CGEM compare to its competitors?
Among the clinical-stage peers tracked alongside CGEM, each company pursues distinct therapeutic areas and mechanisms. Cullinan differentiates through its oncology and immuno-oncology focus, particularly bispecific antibody and EGFR-targeted programs. The UQS platform provides side-by-side pillar comparisons for Pro members.
What is CGEM's market cap bracket?
Cullinan Therapeutics is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers, which is especially relevant for a pre-revenue clinical-stage biotech.
Who founded Cullinan Therapeutics?
Cullinan Therapeutics was founded by Patrick A. Baeuerle in 2016. Baeuerle is a recognized figure in the bispecific antibody and cancer immunotherapy space, and his scientific background has shaped the company's pipeline focus on novel oncology mechanisms.
Is CGEM a long-term quality investment?
As a long-term quality indicator, the UQS Score rates CGEM as Poor, reflecting early-stage fundamentals across most pillars. Long-term quality for a biotech of this type depends heavily on clinical outcomes and capital management — the Risk pillar's Good rating is one constructive signal within an otherwise challenging profile.
What is the main competitive advantage of Cullinan Therapeutics?
Cullinan's pipeline is built around differentiated oncology mechanisms, including bispecific T-cell engagers and EGFR-targeted small molecules. However, the UQS Moat pillar is rated Weak, reflecting that clinical-stage biotechs without approved products have limited durable competitive advantages until regulatory milestones are achieved.
What sector does CGEM belong to?
Cullinan Therapeutics operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) to compare quality profiles across the sector.
Is CGEM a growth stock or value stock?
Based on UQS pillar labels, CGEM carries a Weak Growth rating and an Elevated Valuation rating — a combination that fits neither classic growth nor value profiles. It is best characterized as a speculative clinical-stage biotech where value depends on future pipeline events rather than current financial metrics.
Unlock Full CGEM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for CGEM
- ✓Access underlying financial metrics and trend data
- ✓Compare CGEM side-by-side with sector peers
- ✓Screen for higher-quality healthcare stocks
- ✓Get the complete analyst-style quality breakdown
- ✓Track pillar changes as new data is released
Pro Analysis
CGEM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 10, 2026 | 13.1 | 0.0 | 9.0 | 0.1 | 72.5 | 0.0 | 0.0 |
| May 9, 2026 | 13.1 | 0.0 | 9.0 | 0.0 | 72.5 | 0.0 | 0.0 |
| May 8, 2026 | 13.1 | 0.0 | 9.0 | 0.1 | 72.5 | 0.0 | 0.0 |
| Apr 2, 2026 | 13.1 | 0.0 | 9.0 | 0.1 | 72.0 | 0.0 | — |
CGEM — Pillar Breakdown
Quality
— 0.0/100 (25%)Cullinan Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.1/100 (20%)Cullinan Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 72.4/100 (15%)Cullinan Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Cullinan Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Cullinan Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CGEM.
Score Composition
Financial Data
More Stock Analysis
How is the CGEM UQS Score Calculated?
The UQS (Unified Quality Score) for Cullinan Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Cullinan Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Cullinan Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.